Precigen, Inc. (NASDAQ: PGEN) is a Healthcare company (Biotechnology) with a market capitalization of $1.5B. The Maz Rating grades it against the other companies in its sector.
Precigen, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.29, Precigen, Inc. trades at 63.0x trailing earnings, 9.8x sales and 18.4x book value, with an EV/EBITDA of 39.8. Over the last twelve months it generated about $157M of revenue and $24M of net income. It runs a gross margin of 91.0%, an operating margin of 21.4% and a net margin of 15.6%. It shows return on equity of 57.9%, return on invested capital of 18.3% and a free cash flow yield of -4.9%. On the balance sheet: a debt-to-equity ratio of 1.18 and a current ratio of 5.58. Over the past 52 weeks the share price ranged from $3.04 to $8.98, with a beta of 0.98.
Precigen, Inc. does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 11 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.